Document is current

Article History

Received: 10 September 2025

Accepted: 1 July 2026

First Online: 10 July 2026

Declarations

:

: This study entitled “Evaluation of safety and motivation status of patients with cerebellar ataxia after intrathecal treatment with mesenchymal stem cells “was performed following the Declaration of Helsinki Ethical Principles and approved by the Ethics Committee of the Mashhad University of Medical Sciences, Mashhad, Iran (IR.MUMS.REC.1401.128 at 2022/07/02). Also, this clinical trial was registered with the Iranian Registry of Clinical Trials (ID: IRCT20160809029275N3 at 2022/08/31). All patients or their representatives signed an informed consent form to participate in this clinical trial.

: Not applicable.

: Professor Dr. Karim Nayernia serves as Director of the International Center for Personalized Medicine (P7MEDICINE), Düsseldorf, Germany. Dr. Amirreza Boroumand serves as Scientific Collaborator and Head of the P7 Neuro Department at P7MEDICINE / International Center for Personalized Medicine, Düsseldorf, Germany. Dr. Mohammad Dashtkoohi and Dr. Hamid Khodayari serve as Scientific and Research Assistants at P7MEDICINE / International Center for Personalized Medicine, Düsseldorf, Germany. These affiliations are institutional and academic in nature and are disclosed in accordance with the journal’s competing interests policy. The authors declare that P7MEDICINE did not provide commercial funding, consultancy payments, honoraria, employment-related financial benefits, equity interests, advisory fees, products, services, or any other commercial support related to the design, conduct, analysis, interpretation, or publication of this study. The remaining authors declare that they have no competing interests.